Iran increases production of radiopharmaceuticals to 70 items

Tehran, IRNA – The head of the Atomic Energy Organization of Iran (AEOI) says Iran has increased the number of domestically produced radiopharmaceuticals from 50 in the year 1402 (March 2023–March 2024) to 70 at present.
Speaking at a ceremony unveiling the latest achievements of the Nuclear Science and Technology Research Institute, AEOI chief Mohammad Eslami said that Iran had previously announced the production of 50 radiopharmaceuticals, with another 20 in various stages of research and development.
“In the year 1402, at this very location and at this same exhibition, we announced that we had 50 produced radiopharmaceuticals and that 20 more were in the research phase and at different stages,” he said. “Today, I would like to inform you that we have reached 70 radiopharmaceuticals.”
Eslami described the AEOI as a scientific, research-oriented and industrial body, saying it has become “a successful symbol of keeping the cycle of creativity and innovation alive,” a process in which scientific knowledge is converted into products in the shortest possible time.
The unveiling ceremony took place on the sidelines of the 26th International Exhibition of Research, Technology and Tech-Market, during which the most important achievements of the Nuclear Science and Technology Research Institute were introduced and unveiled.
The event was attended by Vice President Mohammad Reza Aref, Presidential Deputy for Science, Technology and Knowledge-Based Economy Hossein Afshin, and a number of senior officials from Iran’s nuclear industry.
The newly unveiled achievements include the therapeutic radiopharmaceutical 177Lu-Alpha-MSH, the diagnostic radiopharmaceutical 68Ga-Alpha-MSH, an automated system for producing radiopharmaceuticals used in the treatment of bone pain, and the launch of the National Nuclear Education Network.
These products and initiatives are considered among the most significant technological achievements and strategic measures presented by Eslami at the exhibition.


